A145020 Stock Overview
Develops and manufactures biopharmaceuticals in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A145020 from our risk checks.
Hugel, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩284,500.00 |
| 52 Week High | ₩301,000.00 |
| 52 Week Low | ₩131,600.00 |
| Beta | 0.60 |
| 11 Month Change | 7.56% |
| 3 Month Change | 27.29% |
| 1 Year Change | 102.78% |
| 33 Year Change | 55.55% |
| 5 Year Change | 131.55% |
| Change since IPO | 407.14% |
Recent News & Updates
An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued
Sep 13
There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price
Aug 09Recent updates
An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued
Sep 13There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price
Aug 09Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)
Jun 10Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly
Apr 19Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest
Mar 29Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings
Mar 05Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)
Mar 04Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?
Mar 19What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?
Feb 25Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?
Feb 04
The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?
Jan 17Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 29Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?
Dec 14How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?
Nov 24Shareholder Returns
| A145020 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 11.4% | -0.5% | -0.5% |
| 1Y | 102.8% | 58.1% | 7.3% |
Return vs Industry: A145020 exceeded the KR Biotechs industry which returned 58.1% over the past year.
Return vs Market: A145020 exceeded the KR Market which returned 7.3% over the past year.
Price Volatility
| A145020 volatility | |
|---|---|
| A145020 Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A145020 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A145020's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 594 | Ji-hoon Sohn | www.hugel.co.kr |
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name.
Hugel, Inc. Fundamentals Summary
| A145020 fundamental statistics | |
|---|---|
| Market cap | ₩3.12t |
| Earnings (TTM) | ₩111.17b |
| Revenue (TTM) | ₩343.49b |
28.1x
P/E Ratio9.1x
P/S RatioIs A145020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A145020 income statement (TTM) | |
|---|---|
| Revenue | ₩343.49b |
| Cost of Revenue | ₩81.70b |
| Gross Profit | ₩261.80b |
| Other Expenses | ₩150.62b |
| Earnings | ₩111.17b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.13k |
| Gross Margin | 76.22% |
| Net Profit Margin | 32.37% |
| Debt/Equity Ratio | 2.9% |
How did A145020 perform over the long term?
See historical performance and comparison